These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2994898)

  • 1. Recombinant vaccinia viruses as live virus vectors for vaccine antigens: memorandum from a WHO/USPHS/NIBSC meeting.
    Bull World Health Organ; 1985; 63(3):471-7. PubMed ID: 2994898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to viral antigens in man and their relevance to vaccine development: memorandum from a WHO meeting.
    Bull World Health Organ; 1983; 61(6):935-40. PubMed ID: 6609010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection.
    Ramshaw IA; Andrew ME; Phillips SM; Boyle DB; Coupar BE
    Nature; 1987 Oct 8-14; 329(6139):545-6. PubMed ID: 3498904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Perspectives on recombinant live vaccines].
    Ishii K
    Nihon Rinsho; 2008 Oct; 66(10):1903-7. PubMed ID: 18939488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
    Taylor J; Paoletti E
    Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
    Murphy BR; Collins PL
    Bull World Health Organ; 1997; 75(4):307-13. PubMed ID: 9342889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B vaccines prepared from yeast by recombinant DNA techniques: memorandum from a WHO meeting.
    Bull World Health Organ; 1985; 63(1):57-61. PubMed ID: 3886186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen.
    Flexner C; Murphy BR; Rooney JF; Wohlenberg C; Yuferov V; Notkins AL; Moss B
    Nature; 1988 Sep; 335(6187):259-62. PubMed ID: 2842693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live recombinant vaccines using genetically engineered vaccinia virus.
    Paoletti E; Perkus ME; Piccini A
    Antiviral Res; 1985; Suppl 1():301-7. PubMed ID: 3866514
    [No Abstract]   [Full Text] [Related]  

  • 11. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
    Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Viral vaccines produced by gene technology and synthesis].
    Hess RG
    Tierarztl Prax; 1986; 14(1):9-14. PubMed ID: 2424142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
    Breathnach CC; Rudersdorf R; Lunn DP
    Vet Immunol Immunopathol; 2004 Apr; 98(3-4):127-36. PubMed ID: 15010222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective vaccination of ferrets against canine distemper with recombinant pox virus vaccines expressing the H or F genes of rinderpest virus.
    Jones L; Tenorio E; Gorham J; Yilma T
    Am J Vet Res; 1997 Jun; 58(6):590-3. PubMed ID: 9185963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006.
    Ferguson M; Kurane I; Wimalaratne O; Shin J; Wood D;
    Vaccine; 2007 Jul; 25(29):5233-43. PubMed ID: 17590244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
    Kantor J; Irvine K; Abrams S; Snoy P; Olsen R; Greiner J; Kaufman H; Eggensperger D; Schlom J
    Cancer Res; 1992 Dec; 52(24):6917-25. PubMed ID: 1458480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second meeting of the WHO Collaborating Centres on AIDS: Memorandum from a WHO meeting.
    Bull World Health Organ; 1986; 64(1):37-46. PubMed ID: 3015444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.
    de Waal L; Wyatt LS; Yüksel S; van Amerongen G; Moss B; Niesters HG; Osterhaus AD; de Swart RL
    Vaccine; 2004 Feb; 22(8):923-6. PubMed ID: 15161069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune response to vaccinia virus is significantly reduced after scarification with TK- recombinants as compared to wild-type virus.
    Phillpotts RJ; Lescott T; Gates AJ; Jones L
    Acta Virol; 2000; 44(3):151-6. PubMed ID: 11155357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.